Kyverna Therapeutics: Summary

Kyverna Therapeutics

Biopharmaceutical, healthcare, cell therapy, autoimmune diseases

Kyverna offers a pioneering approach to treating autoimmune diseases through advanced CAR T-cell therapies, aiming for long-lasting remission and improved patient outcomes.

Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients suffering from autoimmune diseases. Their lead product, KYV-101, aims to provide long-term remission through CAR T-cell therapy.

Patient-centered approach; Durable disease-clearing CAR T-cell therapy; Active clinical trials for multiple autoimmune diseases; Next-generation chimeric antigen receptor (CAR) T-cell therapies

Kyverna's therapies are most valuable for patients with autoimmune diseases such as lupus nephritis, multiple sclerosis, myasthenia gravis, stiff person syndrome, and systemic sclerosis.

Innovative application of CAR T-cell therapy for autoimmune diseases; Comprehensive clinical trial programs across multiple conditions; Patient-centric model that prioritizes patient experience and outcomes

Kyverna's strengths lie in its innovative therapeutic approach, strong clinical trial pipeline, and commitment to patient-centered care, which positions it favorably in the biopharmaceutical landscape.

Kyverna positions itself as a leader in the development of cell therapies specifically tailored for autoimmune diseases, setting a new standard in treatment efficacy and patient care.

The target users include patients suffering from autoimmune diseases, healthcare providers looking for innovative treatment options, and investors interested in biopharmaceutical advancements.

Participate in clinical trials

• CAR T-cell therapy

• autoimmune diseases

• clinical trials

• biopharmaceuticals

We Develop Life Changing Medicines for Patients Living With Autoimmune Diseases

Innovative, compassionate, authoritative

Kyverna is unique in its focus on leveraging CAR T-cell therapy, traditionally used for hematological malignancies, to target B cell-driven autoimmune diseases, which is a novel application in the field.

Kyverna's brand identity is centered around innovation, patient empowerment, and a commitment to transforming the treatment landscape for autoimmune diseases.

2018-01-01

• Jeffrey Greve